Clinical trials: Biological Therapy
Focal Epilepsy
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination…
- Trial name
- NCT00855738
- Testing
- Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide
- Volunteers
- 111 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Osteoarthritis, Knee
Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
The study is being conducted to investigate the safety and activity of TissueGene-C injected into the knee joint of patients with chronic degenerative joint disease (DJD) who will be undergoing total knee replacement.
- Trial name
- TGC-03-01 (NCT00599248)
- Testing
- TissueGene-C
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Kolon TissueGene, Inc.
Inflammatory Disease, Disease Crohn
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
Study Design: A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in…
- Conditions
- Inflammatory Disease, Disease Crohn, Bowel Disease
- Trial name
- DIRECTCD (NCT06059989)
- Testing
- Infliximab subcutaneous, Immunosuppressive Agents
- Where
- Netherlands
- Volunteers
- 158 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetic Foot Ulcer
MIRODERM H2H DFU Study
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
- Trial name
- H2H-DFU (NCT03232333)
- Testing
- Biologic wound graft
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Miromatrix Medical Inc.
Idiopathic Scoliosis
Effectiveness of a Novel Scoliosis Therapy Using a Standing Scoliosis Therapy Device With Biological Feedback Mechanism
This study evaluates the effectiveness of a novel standing scoliosis therapy device with a biofeedback mechanism in children and adolescents with adolescent idiopathic scoliosis (AIS).
- Trial name
- NCT07585110
- Testing
- SkolioMaster Biofeedback Standing Scoliosis Therapy Device, SKOL-AS Scoliosis Therapy Device, FITS Physiotherapy (Functional Individual Therapy of Scoliosis)
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Centrum Medyczne Katarzyna Smółka
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or…
- Trial name
- COMETA (NCT06897748)
- Testing
- Tozorakimab
- Where
- 12 sites in Russia
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004197
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
Intrahepatic Cholangiocarcinoma
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases.
- Trial name
- PM-CARE (NCT06375915)
- Testing
- radioembolization with Y-90, Durvalumab, Cisplatin
- Where
- 4 sites in Italy
- Volunteers
- 33 people
- Sponsor
- Francesco De Cobelli
Fabry Disease
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have never received any treatment (eg.
- Trial name
- NCT06114329
- Testing
- AL01211
- Where
- 6 sites in China
- Volunteers
- 16 people
- Sponsor
- AceLink Therapeutics, Inc.
Hairy Cell Leukemia
LMB-2 to Treat Hairy Cell Leukemia
Background: About 80% of patients with hairy cell leukemia (HCL) have tumor cells that have a protein on their surface called cluster of differentiation 25 (CD25).
- Trial name
- NCT00321555
- Testing
- Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Oligometastatic Prostate Cancer
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis).
- Trial name
- RADIOSA (NCT03940235)
- Testing
- Androgen deprivation therapy (ADT), SBRT
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Depression, Anxiety
Chinese Herb for the Treatment of Depression and Anxiety Disorders
Anxiety and depression are currently among the ten most important public health concerns, and in recent years, have reached epidemic proportions.
- Trial name
- NCT03323697
- Testing
- SZ-05, Escitalopram Pill
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Mazra Mental Health Center
Hypoxia
Clinical Validation of Vital-PICASO for Predicting Hypoxia Within 24 Hours in General Ward Inpatients
The purpose of this retrospective study is to evaluate the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypoxia within 24 hours using…
- Trial name
- NCT07742813
- Where
- South Korea
- Volunteers
- 2,250 people
- Sponsor
- Huinno AIM
Connective Tissue Diseases, Thrombocytopenia
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.
- Trial name
- NCT05998759
- Testing
- Telitacicept
- Where
- 23 sites in China
- Volunteers
- 296 people
- Sponsor
- Beijing Hospital
Spondyloarthritis
Socio-economic Determinants for Acceptance and Choice of Biological Treatment
This was a cross-sectional study conducted at National center for rheumatic diseases, Nepal on SpA patient refractory to initial treatment with conventional anti rheumatic drugs.
- Trial name
- NCT04369651
- Volunteers
- 117 people
- Sponsor
- National Center for Rheumatic Diseases, Nepal
Olfactory Dysfunction, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Neural Dissimilarity in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Biologics
This project will focus on rehabilitation of olfactory dysfunction in patients with chronic rhinosinusitis with polyps given biological treatment based on functional magnetic resonance imaging.
- Conditions
- Olfactory Dysfunction, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Functional Magnetic Resonance Imaging (fMRI)
- Trial name
- NCT07819162
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bladder Cancer, Kidney Cancer
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00016237
- Testing
- tucotuzumab celmoleukin
- Where
- 2 sites in United States
- Sponsor
- EMD Serono
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
- Trial name
- NCT06919666
- Testing
- NT219
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.